Hodgkin Lymphoma
News
CHMP recommends drug for relapsed/refractory cHL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the anti-PD-1 therapy...
News
Most blood cancer mutations due to DNA replication errors
A new study supports the idea that most cancer-driving mutations are a result of DNA replication errors, not heredity or lifestyle/environmental...
News
Preterm births more common in cancer survivors
Women diagnosed with cancer during their childbearing years have an increased risk of preterm births, according to research published in JAMA...
Feature
Unavoidable, random DNA replication errors are the most common cancer drivers
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...
News
Veterans don’t have higher risk of leukemia, lymphoma
People who have served in the Armed Forces do not have an increased risk of leukemia or lymphoma, according to research published in Cancer...
News
FDA approves pembrolizumab to treat cHL
The US Food and Drug Administration (FDA) has granted accelerated approval for pembrolizumab (Keytruda) as a treatment for adult and pediatric...
News
Family history impacts risk of second cancer after HL
A new study suggests Hodgkin lymphoma (HL) survivors have a high risk of developing a second malignancy, particularly if they have a family...
News
Immunotherapy receives fast track designation
The US Food and Drug Administration (FDA) has granted fast track designation to CMD-003 (baltaleucel-T) for patients with relapsed/refractory...
News
Styrene exposure linked to myeloid leukemia, HL
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that,...
News
How EBV causes lymphoma, other cancers
among uninfected cells (blue) Image courtesy of Benjamin Chaigne-Delalande New research published in Nature Communications appears to explain how...
From the Journals
Long view shows doubling of survival in non-Hodgkin lymphoma
The 5-year relative survival rate for non-Hodgkin lymphoma in the United States went from 33% in 1950-1954 to 71.2% in 2008-2013.